| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 2,215 | 2,415 | 2,508 | 2,522 | 2,582 | 2,850 | 2,922 | 3,125 | 2,179 | 2,808 | 2,781 | 2,931 | 4,079 | 3,725 | 3,662 | 3,580 | 3,812 | 4,274 | 4,299 | 4,322 | 4,452 | 4,873 | 4,880 | 4,981 | 5,134 | 5,633 | 5,596 | 5,664 | 5,896 | 6,365 |
| Expenses | 1,981 | 2,141 | 2,222 | 2,220 | 2,218 | 2,427 | 2,482 | 2,542 | 2,159 | 2,470 | 2,370 | 2,456 | 3,245 | 3,102 | 3,052 | 3,083 | 3,317 | 3,699 | 3,780 | 3,814 | 3,909 | 4,219 | 4,237 | 4,303 | 4,411 | 4,774 | 4,765 | 4,823 | 4,990 | 5,362 |
| EBITDA | 234 | 274 | 286 | 302 | 364 | 423 | 440 | 583 | 21 | 337 | 411 | 475 | 835 | 623 | 610 | 497 | 495 | 575 | 519 | 508 | 543 | 654 | 643 | 677 | 724 | 859 | 831 | 841 | 906 | 1,002 |
| Operating Profit % | 10 % | 11 % | 11 % | 11 % | 14 % | 15 % | 15 % | 13 % | 1 % | 11 % | 14 % | 14 % | 14 % | 17 % | 16 % | 13 % | 13 % | 13 % | 11 % | 11 % | 12 % | 13 % | 13 % | 13 % | 13 % | 15 % | 14 % | 14 % | 15 % | 15 % |
| Depreciation | 95 | 97 | 98 | 105 | 144 | 155 | 157 | 164 | 160 | 149 | 125 | 139 | 141 | 145 | 149 | 166 | 148 | 155 | 153 | 159 | 167 | 163 | 167 | 190 | 177 | 185 | 185 | 211 | 215 | 218 |
| Interest | 76 | 81 | 84 | 85 | 126 | 134 | 137 | 135 | 127 | 122 | 101 | 99 | 95 | 95 | 94 | 95 | 93 | 93 | 100 | 95 | 106 | 111 | 113 | 119 | 116 | 118 | 110 | 115 | 108 | 110 |
| Profit Before Tax | 63 | 96 | 103 | 112 | 94 | 134 | 145 | 284 | -267 | 66 | 185 | 238 | 599 | 383 | 368 | 236 | 254 | 327 | 266 | 254 | 270 | 379 | 363 | 368 | 430 | 557 | 536 | 516 | 583 | 675 |
| Tax | 39 | 42 | 53 | 39 | 45 | 51 | 55 | 74 | -41 | 7 | 51 | 68 | 99 | 116 | 124 | 139 | -70 | 114 | 104 | 108 | 97 | 130 | 109 | 110 | 115 | 162 | 157 | 101 | 142 | 181 |
| Net Profit | 23 | 54 | 50 | 73 | 49 | 83 | 90 | 210 | -226 | 59 | 134 | 170 | 501 | 267 | 243 | 97 | 324 | 213 | 162 | 146 | 173 | 249 | 254 | 258 | 316 | 396 | 379 | 415 | 441 | 494 |
| EPS in ₹ | 2.44 | 4.56 | 4.10 | 6.10 | 4.11 | 6.20 | 6.62 | 15.77 | -14.96 | 4.33 | 9.38 | 11.77 | 34.03 | 17.24 | 15.88 | 6.27 | 22.05 | 14.19 | 10.67 | 10.05 | 11.59 | 16.20 | 17.06 | 17.65 | 21.23 | 26.34 | 25.89 | 27.10 | 30.10 | 33.19 |
Apollo Hospitals
Apollo Hospitals
7,464.50
+5.50
(0.07%)
Key Fundamentals
Market Cap
1,07,328.06 Cr
EPS
100.56
PE Ratio
62.03
Dividend Yield
0.17 %
Industry
Healthcare Services 52 Week High
8,099.50
52 Week Low
6,001.00
PB Ratio
11.80
Debt to Equity
0.61
Sector
Hospitals Analyst Rating and Forecast
- By Refinitiv from26 analysts
Actual
Company News
View All News
Apollo Hospitals Enterprise Limited received in-principle approval from BSE and NSE for issuing and allotting a maximum of 21,56,770 equity shares of Rs. 5 each under the Apollo Hospitals Enterprise Limited - Employee Stock Option Plan 2024. BSE granted approval via letter dated November 7, 2025, and NSE provided similar approval on the same date. The approvals are subject to various conditions including regulatory compliance, payment of prescribed fees, receipt of statutory approvals, and adherence to listing agreement conditions. Both exchanges reserve the right to withdraw approval if submitted information is found incomplete or incorrect.
Apollo Hospitals Enterprise plans to add 1,600 beds over the next 14 months, targeting 18% revenue growth in its hospital business over three years. Managing Director Suneeta Reddy stated that existing operations will grow at 12% while new beds will contribute an additional 5% to revenue. The company added 148 pharmacy stores and expects double-digit margins from the pharmacy business within three to four years. Apollo has a remaining capital expenditure of Rs 5,000 crore as part of a broader plan to add 4,300 beds with total capex of Rs 8,300 crore. The company targets improving Ebitda margins to 25% through better case mix, operating leverage, and cost efficiencies. Apollo Hospitals shares closed down 1.8% at Rs 7,642 on the NSE.
Apollo Hospitals Plans Revenue Generation from Six New Hospital Openings, Explores Uzbekistan Expansion
Nov 07, 2025
Nov 07, 2025Apollo Hospitals announced plans to generate revenue from six new hospitals that are set to open soon. The healthcare company is also discussing potential business opportunities in Uzbekistan as part of its expansion strategy.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,157.60 | #1 1,12,546.09 | 83.38 | 7,184.10 | #1 28.65 | 1,076 | #1 74.34 | 56.08 | |
7,464.50 | #2 1,07,328.06 | #5 62.03 | #1 21,994.30 | #7 14.76 | #1 1,505 | #4 24.84 | 39.09 | |
934.70 | 70,565.94 | 67.12 | 7,849.70 | 13.25 | 809 | 70.27 | 28.83 | |
2,006.80 | 41,011.13 | 48.16 | 5,575.00 | 12.29 | 790 | 30.03 | 67.61 | |
670.10 | 34,719.29 | 94.18 | 4,286.70 | 15.12 | 337 | 14.65 | 41.07 | |
1,204.80 | 32,383.87 | 57.42 | 3,771.40 | 12.59 | 481 | 21.10 | 37.74 | |
661.75 | 26,479.19 | 74.69 | 3,067.00 | 21.98 | 415 | -40.35 | 35.99 | |
1,337.00 | 13,578.46 | 53.41 | 1,566.90 | 17.46 | 244 | -4.30 | 45.82 | |
753.80 | 10,628.59 | 255.86 | 2,257.70 | 17.03 | 49 | 0.00 | 55.83 | |
1,457.20 | 9,554.28 | #1 48.00 | 1,290.20 | 17.77 | 194 | 11.00 | 39.00 |
Growth Rate
Revenue Growth
14.76 %
Net Income Growth
60.97 %
Cash Flow Change
11.26 %
ROE
36.18 %
ROCE
2.58 %
EBITDA Margin (Avg.)
12.43 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 6,479 | 7,360 | 8,119 | 8,613 | 9,183 | 11,338 | 11,417 | 13,269 | 14,428 | 16,753 | 20,657 |
| Fixed Assets | 3,244 | 3,997 | 4,591 | 4,773 | 4,982 | 7,432 | 6,778 | 8,296 | 8,520 | 9,664 | 10,988 |
| Current Assets | 1,939 | 1,975 | 2,129 | 2,220 | 2,282 | 2,647 | 3,641 | 4,061 | 4,337 | 5,280 | 7,029 |
| Capital Work in Progress | 533 | 562 | 347 | 712 | 822 | 236 | 234 | 46 | 610 | 873 | 921 |
| Investments | 146 | 352 | 406 | 352 | 462 | 434 | 1,343 | 816 | 574 | 986 | 2,487 |
| Other Assets | 2,557 | 2,448 | 2,775 | 2,776 | 2,918 | 3,237 | 3,062 | 4,112 | 4,725 | 5,230 | 6,261 |
| Total Liabilities | 6,479 | 7,360 | 8,119 | 8,613 | 9,183 | 11,338 | 11,417 | 13,269 | 14,428 | 16,753 | 20,657 |
| Current Liabilities | 1,076 | 1,250 | 963 | 1,567 | 1,956 | 2,337 | 2,038 | 2,434 | 3,325 | 4,665 | 4,579 |
| Non Current Liabilities | 2,159 | 2,701 | 3,718 | 3,662 | 3,759 | 5,531 | 4,577 | 4,932 | 4,572 | 4,768 | 7,426 |
| Total Equity | 3,244 | 3,409 | 3,438 | 3,384 | 3,469 | 3,470 | 4,802 | 5,903 | 6,531 | 7,321 | 8,653 |
| Reserve & Surplus | 3,101 | 3,262 | 3,240 | 3,182 | 3,264 | 3,270 | 4,531 | 5,551 | 6,126 | 6,864 | 8,140 |
| Share Capital | 70 | 70 | 70 | 70 | 70 | 70 | 72 | 72 | 72 | 72 | 72 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 103 | 39 | -52 | 24 | -20 | 95 | 45 | 158 | -113 | 72 | 73 |
| Investing Activities | -759 | -888 | -1,152 | -405 | -711 | -289 | -880 | -747 | -857 | -1,537 | -3,381 |
| Operating Activities | 470 | 597 | 623 | 537 | 905 | 1,293 | 1,265 | 1,696 | 1,377 | 1,920 | 2,136 |
| Financing Activities | 392 | 330 | 477 | -109 | -215 | -910 | -340 | -792 | -633 | -311 | 1,317 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 29.82 % | 29.82 % | 29.82 % | 29.33 % | 29.33 % | 29.33 % | 29.33 % | 29.33 % | 29.33 % | 29.33 % | 29.33 % | 29.33 % | 29.33 % | 29.33 % | 29.33 % | 29.33 % | 29.34 % | 29.34 % | 28.02 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 45.63 % | 43.92 % | 45.37 % | 45.27 % | 42.74 % | 43.49 % | 44.20 % |
| DIIs | 9.16 % | 10.84 % | 12.24 % | 12.13 % | 12.45 % | 14.89 % | 14.59 % | 16.56 % | 17.76 % | 16.31 % | 18.60 % | 17.97 % | 19.55 % | 21.14 % | 19.95 % | 19.98 % | 22.29 % | 21.34 % | 21.12 % |
| Government | 0.23 % | 0.23 % | 0.23 % | 0.23 % | 0.23 % | 0.23 % | 0.23 % | 0.23 % | 0.23 % | 0.23 % | 0.23 % | 0.23 % | 0.23 % | 0.23 % | 0.23 % | 0.23 % | 0.23 % | 0.23 % | 0.23 % |
| Public / Retail | 4.07 % | 3.99 % | 4.24 % | 4.03 % | 4.27 % | 4.48 % | 4.23 % | 4.13 % | 4.04 % | 3.90 % | 4.04 % | 3.70 % | 3.74 % | 3.81 % | 3.62 % | 3.65 % | 3.81 % | 3.98 % | 4.44 % |
| Others | 56.73 % | 55.13 % | 53.47 % | 54.29 % | 53.73 % | 51.07 % | 51.63 % | 49.75 % | 48.64 % | 50.23 % | 47.80 % | 48.76 % | 1.52 % | 1.57 % | 1.50 % | 1.54 % | 1.60 % | 1.62 % | 1.99 % |
| No of Share Holders | 67,091 | 75,153 | 98,452 | 99,135 | 1,26,226 | 1,46,320 | 1,35,923 | 1,31,636 | 1,31,937 | 1,20,030 | 1,31,565 | 1,19,578 | 1,30,664 | 1,27,754 | 1,19,245 | 1,27,802 | 1,34,058 | 1,41,007 | 1,60,556 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 6 | 5 | 6 | 6 | 3 | 11.75 | 15 | 16 | 12.66 |
| Dividend Yield (%) | 0.00 | 0.56 | 0.41 | 0.53 | 0.21 | 0.07 | 0.27 | 0.24 | 0.24 | 0.17 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 21 Aug 2021 |  Dividend | ₹ 3.00 /share | 18 Aug 2021 | 3,244.80 | 4,746.50 |
| 20 Aug 2022 | Dividend | ₹ 11.75 /share | 18 Aug 2022 | 3,524.30 | 4,135.35 |
| 24 Feb 2023 | Dividend | ₹ 6.00 /share | 24 Feb 2023 | 4,355.10 | 4,448.85 |
| 19 Aug 2023 | Dividend | ₹ 9.00 /share | 18 Aug 2023 | 4,646.10 | 4,848.35 |
| 20 Feb 2024 | Dividend | ₹ 6.00 /share | 20 Feb 2024 | 6,179.35 | 6,656.25 |
| 17 Aug 2024 | Dividend | ₹ 10.00 /share | 16 Aug 2024 | 5,903.45 | 6,686.90 |
| 30 Aug 2024 |  Annual General Meeting | NA | 30 Aug 2024 | 6,704.00 | 6,855.95 |
| 06 Nov 2024 |  Quarterly Result Announcement | NA | 06 Nov 2024 | 7,092.60 | 6,966.30 |
| 10 Feb 2025 | Quarterly Result Announcement | NA | 10 Feb 2025 | 6,828.10 | 6,790.55 |
| 15 Feb 2025 | Dividend | ₹ 9.00 /share | 14 Feb 2025 | 6,790.55 | 6,266.65 |
| 30 May 2025 | Quarterly Result Announcement | NA | 30 May 2025 | 6,974.00 | 6,923.00 |
| 12 Aug 2025 | Quarterly Result Announcement | NA | 12 Aug 2025 | 7,352.50 | 7,259.00 |
| 19 Aug 2025 | Dividend | ₹ 10.00 /share | 19 Aug 2025 | 6,923.00 | 7,822.50 |
| 29 Aug 2025 | Annual General Meeting | NA | 29 Aug 2025 | 6,923.00 | 7,726.60 |
| 06 Nov 2025 | Quarterly Result Announcement | NA | 06 Nov 2025 | 7,671.00 | 7,813.25 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome9 days ago
9 days agoIntimation Of Receipt Of In - Principle Approval From BSE Limited And National Stock Exchange Of India Limited For Issue And Allotment Of Maximum Of 2156770 Equity Shares Of Rs.5/- Each Under Apollo Hospitals Enterprise Limited - Employee Stock Option PlaNov 08, 2025
Nov 08, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 07, 2025
Nov 07, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 06, 2025
Nov 06, 2025Board Meeting Outcome for Outcome Of Board MeetingNov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 30, 2025
Oct 30, 2025Board Meeting Intimation for Notice Of The Board MeetingOct 14, 2025
Oct 14, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Oct 08, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionOct 04, 2025
Oct 04, 2025Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (Listing Regulations).Sep 24, 2025
Sep 24, 2025Closure of Trading WindowSep 23, 2025
Sep 23, 2025Announcement under Regulation 30 (LODR)-AcquisitionSep 12, 2025
Sep 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 12, 2025
Sep 12, 2025Board Meeting Outcome for Outcome Of The Board MeetingSep 12, 2025
Sep 12, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 30, 2025
Aug 30, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 29, 2025
Aug 29, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 29, 2025
Aug 29, 2025Newspaper Advertisement(S) Regarding Notice Of Special Window For Re-Lodgement Of Transfer Requests Of Physical SharesAug 22, 2025
Aug 22, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 22, 2025
Aug 22, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 20, 2025
Aug 20, 2025Update On Outcome Of The Board Meeting - 12Th August 2025Aug 14, 2025
Aug 14, 2025Reply To Your Mail Ref No. L/SURV/ONL/PV/AA/ 2025-2026 / 352 Dated 14Th August 2025Aug 14, 2025
Aug 14, 2025Clarification sought from Apollo Hospitals Enterprise LtdAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 12, 2025
Aug 12, 2025As Per Annexure EnclosedAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-AcquisitionAug 12, 2025
Aug 12, 2025Board Meeting Outcome for Outcome Of The Board MeetingAug 12, 2025
Aug 12, 2025Submission Of Newspaper Advertisements - 44Th Annual General Meeting & IEPF Transfer NoticeAug 08, 2025
Aug 08, 2025Business Responsibility and Sustainability Reporting (BRSR)Aug 07, 2025
Aug 07, 2025Reg. 34 (1) Annual Report.Aug 06, 2025
Aug 06, 2025Disclosure Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (Listing Regulations)
Aug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 29, 2025
Jul 29, 2025Board Meeting Intimation for Notice For The Board MeetingJul 17, 2025
Jul 17, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 08, 2025
Jul 08, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 08, 2025
Jul 08, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 01, 2025
Jul 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 01, 2025
Jul 01, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Scheme of ArrangementJun 30, 2025
Jun 30, 2025Closure of Trading WindowJun 23, 2025
Jun 23, 2025Announcement under Regulation 30 (LODR)-AcquisitionJun 10, 2025
Jun 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJun 06, 2025
Jun 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 31, 2025
May 31, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 31, 2025
May 31, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionMay 31, 2025
May 31, 2025Mutual Fund Holdings
Kotak Arbitrage Fund Direct-Growth 
Aditya Birla Sun Life Value Direct Fund-Growth 
HDFC Balanced Advantage Fund Direct-Growth 
Tata Focused Fund Direct - Growth 
Mirae Asset Large & Midcap Fund Direct-Growth 
Bajaj Finserv Flexi Cap Fund Direct-Growth 
Bandhan Large & Mid Cap Fund Direct-Growth 
JM Midcap Fund Direct - Growth 
SBI Arbitrage Opportunities Fund Direct-Growth 
Edelweiss Balanced Advantage Fund Direct-Growth 
Franklin India Large Cap Fund Direct-Growth 
Mahindra Manulife Large & Mid Cap Fund Direct - Growth 
Invesco India Arbitrage Fund Direct-Growth 
NJ Balanced Advantage Fund Direct - Growth 
Axis Quant Fund Direct-Growth 
Sundaram Infrastructure Advantage Fund Direct-Growth 
Nippon India Vision Large & Mid Cap Direct-Growth Technical Indicators
RSI(14)
Neutral 39.09
ATR(14)
Volatile 122.93
STOCH(9,6)
Oversold 11.96
STOCH RSI(14)
Neutral 20.19
MACD(12,26)
Bearish -35.32
ADX(14)
Strong Trend 30.95
UO(9)
Bearish 45.59
ROC(12)
Downtrend But Slowing Down -2.89
WillR(14)
Neutral -77.28
About Apollo Hospitals
Apollo Hospitals Enterprise Limited (AHEL) is a leading private healthcare provider in Asia. It operates a network of hospitals, pharmacies, primary care clinics, and diagnostic centers. As of March 31, 2023, AHEL had a capacity of 9,957 beds across 70 hospitals in India and overseas. This includes 8,544 beds in 43 owned hospitals, 305 beds in 11 cradles, 257 beds in 11 day care/short surgical stay centers, and 851 beds in 5 hospitals operated through management contracts. The company has expanded through acquisitions, joint ventures, and new facility launches. AHEL has also diversified into health insurance, retail pharmacy, and digital healthcare platforms. The company has undergone various corporate restructurings to optimize its business operations across different healthcare segments.
Chairperson NamePreetha Reddy
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
